- Conditions
- Pancreatic Cancer
- Interventions
- nal-IRI, 5 fluorouracil, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 29
- States / cities
- Mobile, Alabama • Avondale, Arizona • Phoenix, Arizona + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 929
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Interventions
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol
- Procedure · Drug
- Lead sponsor
- Guerbet
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,076 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Core Biopsy, Fluorouracil, Irinotecan, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quemliclustat, Zimberelimab
- Procedure · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, tacedinaline
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Tampa, Florida • Baltimore, Maryland + 8 more
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
- Interventions
- XmAb®22841, Pembrolizumab (Keytruda®)
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 28
- States / cities
- Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- BBI608, Nab-paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, MM-398
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more
- Conditions
- Metastatic Adenocarcinoma of the Pancreas
- Interventions
- Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)
- Drug
- Lead sponsor
- Eastern Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pancreatic Cancer
- Interventions
- docetaxel, gemcitabine hydrochloride
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 10
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, imatinib mesylate
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Freehold, New Jersey • Hamilton, New Jersey + 3 more
- Conditions
- Pancreatic Cancer
- Interventions
- physiologic testing
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Retifanlimab, Chemotherapy, 9-ING-41
- Drug
- Lead sponsor
- Anwaar Saeed
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
- Interventions
- GVAX Pancreas Vaccine, CRS-207, Chemotherapy, cyclophosphamide
- Biological · Drug
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • La Jolla, California • San Francisco, California + 16 more
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
- Interventions
- V941, Pembrolizumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more
- Conditions
- Pancreatic Cancer
- Interventions
- LDE225+gemcitabine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Salt Lake City, Utah
- Conditions
- Metastatic Adenocarcinoma of the Pancreas
- Interventions
- Irinotecan Liposomal Injection, Oxaliplatin, 5Fluorouracil, Leucovorin, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 63 more
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- sorafenib tosylate, everolimus, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Buffalo, New York
- Conditions
- Pancreatic Neoplasms, Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms, Adenocarcinoma
- Interventions
- Gemcitabine, nab-paclitaxel, Pharmacological ascorbate
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma
- Interventions
- EndoTAG-1, Gemcitabine
- Drug
- Lead sponsor
- SynCore Biotechnology Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 16
- States / cities
- Corona, California • Atlanta, Georgia • Columbus, Georgia + 12 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Albumin-bound paclitaxel (ABI-007), Gemcitabine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 861 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 71 more
- Conditions
- Pancreatic Cancer
- Interventions
- Synthetic Human Secretin
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nab-paclitaxel, Pancreatic Surgical Procedure
- Procedure · Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
- Drug
- Lead sponsor
- Pancreatic Cancer Action Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Pancreatic Cancer
- Interventions
- protein expression analysis, western blotting, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pharynx Cancer, Oral Cavity Cancer, Kidney Cancer, Liver Cancer, Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Prostate Cancer
- Interventions
- [64Cu]CM500, [68Ga]CM500, PET/MR, PET/CT, Blood Collection
- Drug · Device · Procedure
- Lead sponsor
- Lumina Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Grand Rapids, Michigan • New York, New York